

Trends in Outpatient Procedural Sedation: 2007–2018

Pradip P. Kamat, MD, MBA, FCCM,^a Courtney E. McCracken, PhD,^b Harold K. Simon, MD, MBA,^{b,c} Anne Stormorken, MD,^d Michael Mallory, MD, MPH,^e Corrie E. Chumpitazi, MD,^f Joseph P. Cravero, MD^g

abstract

BACKGROUND: Pediatric subspecialists routinely provide procedural sedation outside the operating room. No large study has reported trends in outpatient pediatric procedural sedation. Our purpose in this study was to identify significant trends in outpatient procedural sedation using the Pediatric Sedation Research Consortium.

METHODS: Prospectively collected data from 2007 to 2018 were used for trending procedural sedation. Patient characteristics, medications, type of providers, serious adverse events, and interventions were reported. The Cochran–Armitage test for trend was used to explore the association between the year and a given characteristic.

RESULTS: A total of 432 842 sedation encounters were identified and divided into 3 4-year epochs (2007–2011, 2011–2014, and 2014–2018). There was a significant decrease in infants <3 months of age receiving procedural sedation (odds ratio = 0.97; 95% confidence interval, 0.96–0.98). A large increase was noticed in pediatric hospitalists providing procedural sedation (0.6%–9.5%; $P < .001$); there was a decreasing trend in sedation by other providers who were not in emergency medicine, critical care, or anesthesiology (13.9%–3.9%; $P < .001$). There was an increasing trend in the use of dexmedetomidine (6.3%–9.3%; $P < .001$) and a decreasing trend in the use of chloral hydrate (6.3%–0.01%; $P < .001$) and pentobarbital (7.3%–0.5%; $P < .001$). Serious adverse events showed a nonsignificant increase overall (1.35%–1.75%).

CONCLUSIONS: We report an increase in pediatric hospitalists providing sedation and a significant decrease in the use of chloral hydrate and pentobarbital by providers. Further studies are required to see if sedation services decrease costs and optimize resource use.



^aDivision of Pediatric Critical Care Medicine, ^bDepartments of Pediatrics and ^cEmergency Medicine, School of Medicine, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia; ^dPediatric Emergency Medicine Associates, Scottish Rite Hospital, Children's Healthcare of Atlanta, Atlanta, Georgia; ^eDivision of Pediatric Critical Care Medicine, Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio; ^fDepartment of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas; and ^gDepartment of Anesthesiology, Critical Care and Pain Medicine, Harvard Medical School, Harvard University and Boston Children's Hospital, Boston, Massachusetts

Drs Kamat, Mallory, Stormorken, and Cravero conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript; Drs Simon and Chumpitazi conceptualized and designed the study and critically reviewed the manuscript for important intellectual content; Dr McCracken designed the data collection instruments, collected data, conducted the initial analyses, and reviewed and revised the manuscript; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

DOI: <https://doi.org/10.1542/peds.2019-3559>

Accepted for publication Feb 11, 2020

WHAT'S KNOWN ON THIS SUBJECT: Pediatricians and various pediatric subspecialists provide procedural sedation outside the operating room. There has been an explosive growth in this field in the last decade. Trends in outpatient procedural sedation in terms of medications used, providers, and adverse events remain understudied.

WHAT THIS STUDY ADDS: This study provides the latest trends and progress in outpatient pediatric procedural sedation. We report an increase in pediatric hospitalists providing sedation and a significant decrease in the use of chloral hydrate and pentobarbital by providers between 2008 and 2018.

To cite: Kamat PP, McCracken CE, Simon HK, et al. Trends in Outpatient Procedural Sedation: 2007–2018. *Pediatrics*. 2020;145(5):e20193559

In the last 2 decades, there has been tremendous growth in pediatric procedural sedation outside the operating room provided by various pediatric subspecialists.^{1–3}

Pediatricians and various pediatric subspecialists now routinely provide sedation for a variety of invasive and noninvasive procedures at various locations outside the operating room.^{4–6} Because of the disparate practitioners involved in provision of procedural sedation and the wide variation in practice across institutions, the evaluation and description of global sedation practice are difficult.^{7,8} Furthermore, prospective randomized blinded trials in outpatient sedation are difficult to perform and are limited by cost and resource shortages. Since 2004, the Pediatric Sedation Research Consortium (PSRC), the research arm of the Society for Pediatric Sedation, has collected prospective observational data on sedation and anesthesia encounters from sedation programs in the United States. Multiple peer-reviewed publications from the PSRC have shed light on sedation outcomes data, such as association of adverse events with comorbidities and medications used.^{9–17}

The purpose of this study was to identify trends in outpatient procedural sedation from 2007 to 2018. Evaluating trends in sedation practice provides an opportunity for the clinicians, researchers, and other stakeholders, including patients and their families, to understand how sedation practice may have evolved in the last 2 decades. The sedation community will be informed about changes in providers of sedation, types of procedures for which sedation is provided, type of medications, adverse events, and success rates. Furthermore, studying trends can be used to provide insight into institutions that are contemplating starting a sedation program. This kind of reporting can

allow institutions to understand how their practice aligns with that of a group of high-performing organizations across the country.

METHODS

Study Population and Data Collection

The PSRC is a collaborative group of sedation providers from multiple sedation programs in the United States dedicated to furthering sedation research and optimizing sedation practices in children outside the operating room by collecting prospective observational data from sedation and anesthesia encounters. The Supplemental Information lists programs participating in the PSRC.

The PSRC methods have been well described.^{9,15} A standardized Web-based data collection tool is used to capture deidentified data. Data are stored in a secure-site data system maintained by the Dartmouth Bioinformatics Group. Data collected include patient demographics, diagnoses, reasons for procedural sedation, locations and type of procedures performed, medications and adjuncts used, adverse events, and interventions required for adverse events. The PSRC uses a standardized definition of sedation-related adverse events (Supplemental Information). Painful procedures are listed in the Supplemental Information.

In this study, we used data from the PSRC database from January 1, 2007, to December 31, 2018. All pediatric patients <21 years of age who received procedural sedation outside the operating room during that time frame were included in the study. The main outcome measures were procedural success rates, type of providers, patient age, sex, American Society of Anesthesiologists physical status classification, primary diagnosis, reasons for sedation, medications, type of procedures, fasting times, adverse events, and

interventions. Among adverse events, only serious adverse events (SAEs) were included (Supplemental Information) and were defined as sedation-related events with the potential to cause irreversible neurologic harm. The SAEs are readily identifiable by sedation providers, which allows for standardized data reporting across the PSRC sites.

Although multiple adverse events could occur in a single sedation, the adverse event rate was reported as the number of sedations in which at least one adverse event occurred out of the total number of sedations. Additionally, patients could have undergone more than one procedural sedation and therefore appear multiple times in the data set. For analysis, multiple sedations were considered independently. Because of the nature of data collection of the PSRC, long-term follow-up or subsequent care related to an adverse event could not be obtained.

Statistical Analysis

Descriptive statistics were calculated for all variables of interest and included counts with percentages or medians with interquartile ranges when appropriate. For trend analysis, data were split into 3 4-year epochs (2007–2010, 2011–2014, and 2015–2018) because some of our outcomes, including SAEs, are rare, and this allowed us to have an adequate number of events during modeling. Second, we did not want to burden the audience with too many time points. Time was examined both continuously (when possible), as a year-to-year change, and during epochs that were created on the basis of dividing the cohort into equal time intervals. To explore how patient demographics or sedation characteristics changed over time, the year was treated as an ordinal variable, and the Cochran–Armitage test for trend was used to explore the association between the year and a given characteristic. Given the large

number of observations in this data set, small differences were statistically significant without clear clinical correlation. In an effort to overcome this, logistic regression was used to obtain effect sizes, namely odds ratios (ORs), to aid in the interpretation in trend over time. To estimate the impact of a continuous characteristic, we used linear regression in place of logistic regression, and the effect size is presented as a slope. Multivariable logistic regression was used to examine the effect of multiple risk factors on the outcome of SAE occurrence, and trends for study epochs were examined. Results are presented as ORs with 95% confidence intervals (CIs). Analysis was conducted by using software (SAS version 9.4; SAS Institute, Inc, Cary, NC).

Sensitivity Analysis

Not all PSRC centers contributed data for the entire study period. To evaluate the impact of centers entering or leaving the PSRC, we conducted sensitivity analyses. We included data from institutions that were consistent with data entry for the last decade within the PSRC. Trends in demographic and sedation characteristics were reexamined and compared with results when all PSRC institutions' data contributions were analyzed.

RESULTS

Trends in Patient Demographics

During the study period, a total of 437 842 sedation encounters were analyzed. The demographic distribution of patients for the overall study period and for individual 4-year epochs is shown in Table 1.

From 2007 to 2018, sedation encounters involving patients <1 year showed an overall decrease, which was primarily in children <3 months of age, from 10.6% in the

2007–2010 epoch to 8.0% in the 2015–2018 epoch (OR = 0.97; 95% CI, 0.96–0.98).

Trends in Procedures and Sedation Providers

Trends in sedation providers over the study period are shown in Fig 1. There was an increasing trend seen in pediatric hospitalists providing sedation. In the earliest period (2007–2010), hospitalists accounted for <1% of sedations, but they jumped to 9.5% in the latest period (2015–2018: OR = 1.28; 95% CI, 1.28–1.29; $P < .0001$). A decreasing trend was noted in other sedation providers (radiologists, nurse anesthetists, other advanced practice nurses or physician's assistants, physician trainees, nurses, surgeons, and general pediatricians), with rates decreasing from 13.9% in the earliest epoch to 3.1% in the latest epoch (OR = 0.78; 95% CI, 0.77–0.78; $P < .0001$).

A decreasing trend was noted in procedural sedation for radiologic imaging from 61% to 48% (2007–2011 vs 2014–2018; $P < .0001$), an increase in procedural sedation for hematologic procedures from 13.6% to 21.4% (2007–2011 vs 2014–2018; $P < .0001$) was noted, and a small increase in gastrointestinal procedural sedation from 8.7% to 9.3% (2007–2011 vs 2014–2018; $P < .0001$) was noted. This is shown in Supplemental Table 3. There was no change in the overall procedural success rate through the study epochs (99.7% for all).

Trends in Medications Administered

There was an overall significant, decreasing trend in use of pentobarbital and chloral hydrate, with rates in the earliest epoch of 7.3% (decreased to 0.5%; $P < .0001$) and 6.5% (decreased to <0.1%; $P < .0001$), respectively. Dexmedetomidine showed a bimodal

pattern with increasing use from 2007 to 2009, followed by a decrease and plateau from 2010 to 2014. Since 2014, the use of dexmedetomidine has continued to increase. This pattern is shown in Fig 2. Medications stratified by type of sedation provider are shown in Supplemental Fig 4.

Trends in Adverse Events and Interventions

Trends in rates and type of SAE during the study period are shown in Table 2. The overall SAE rate was 1.78%. Airway obstruction was the most common SAE, occurring in 1.55% of all sedation encounters. There was a small, nonsignificant increase in the SAE rate, from 1.35% to 1.75% (2007–2011 vs 2014–2018). Excluding airway obstruction, the SAE rate was 0.31%, or 3.1 serious events per 1000, with an increase from 0.23% to 0.37% (2007–2011 vs 2014–2018; $P < .0001$). There were no deaths.

Interventions performed in response to adverse events are shown in Supplemental Table 4.

Risk Factors Associated With Adverse Events by Using Multivariable Analysis

A multivariable logistic regression analysis was performed for odds of an SAE by using variables including age; weight; American Society of Anesthesiologists physical status classification; primary diagnosis; comorbidities such as developmental delay, upper respiratory tract infection, asthma, prematurity, and obstructive sleep apnea; and medications and adjuncts administered. Results are shown in Fig 3. There were increased odds of having an SAE in the latest epoch compared with the middle epoch (OR = 1.18; 95% CI, 1.09–1.27; $P < .001$). No difference was noted between the

TABLE 1 Demographic and Sedation Characteristics by Era

Characteristic	Overall (N = 437 842)	2007–2010 (N = 131 959)	2011–2014 (N = 162 954)	2015–2018 (N = 142 929)	P (Test for Trend)	OR (per 1-y Increase)	Slope (per 1-y Increase)
Age, y (n = 437 841), n (%)							
<1	46 164 (10.5)	17 626 (13.4)	16 450 (10.1)	12 088 (8.5)	<.001	0.93	—
1–13	341 017 (77.9)	102 044 (77.3)	126 862 (77.9)	112 111 (78.4)	<.001	1.01	—
≥14	50 660 (11.6)	12 288 (9.3)	19 642 (12.1)	18 730 (13.1)	<.001	1.05	—
Male sex (n = 437 435), n (%)	241 955 (55.3)	72 663 (55.2)	89 740 (55.1)	79 552 (55.7)	.156	1.00	—
Wt, kg ^a	19.0 (12.7–32.6)	17.0 (11.7–28.1)	19.4 (13.0–33.6)	20.0 (13.6–35.7)	<.001	—	0.5-kg increase
ASA (n = 429 487), n (%)							
1	99 806 (23.2)	35 166 (27.2)	32 534 (20.3)	32 106 (23.0)	<.001	0.96	—
2	255 777 (59.6)	71 914 (55.6)	100 509 (62.6)	83 354 (59.7)	<.001	1.03	—
3	72 227 (16.8)	21 724 (16.8)	27 064 (16.9)	23 439 (16.6)	.512	1.00	—
4	1677 (0.4)	491 (0.4)	375 (0.2)	811 (0.6)	<.001	1.06	—
NPO (clear fluids) <2 h, n (%)	423 930 (99)	128 054 (98.9)	157 330 (98.8)	138 546 (99.4)	<.0001	1.07	—
NPO (solids) <6 h, n (%)	407 967 (98.5)	131 959 (100)	147 049 (98.3)	128 959 (97.4)	<.0001	0.75	—
Primary diagnosis, n (%)							
Burn	1899 (0.4)	457 (0.3)	595 (0.4)	847 (0.6)	<.0001	1.05	—
Cardiology	6289 (1.4)	2316 (1.8)	2076 (1.3)	1897 (1.3)	<.0001	0.95	—
Congenital	2927 (0.7)	1077 (0.8)	986 (0.6)	864 (0.6)	<.0001	0.96	—
Craniofacial	4329 (1)	1756 (1.3)	1678 (1)	895 (0.6)	<.0001	0.91	—
Dental	5537 (1.3)	681 (0.5)	1834 (1.1)	3022 (2.1)	<.0001	1.2	—
Dermatology	3232 (0.7)	1133 (0.9)	1166 (0.7)	933 (0.7)	<.0001	0.96	—
Gastrointestinal	44 809 (10.2)	12 858 (9.7)	17 203 (10.6)	14 748 (10.3)	.0002	1.01	—
Hematology-oncology	108 079 (24.7)	28 774 (21.8)	42 503 (26.1)	36 802 (25.7)	<.0001	1.03	—
Immune compromise	540 (0.1)	236 (0.2)	167 (0.1)	137 (0.1)	<.0001	0.91	—
Infection	21 594 (4.9)	7763 (5.9)	8244 (5.1)	5587 (3.9)	<.0001	0.95	—
Liver	2021 (0.5)	791 (0.6)	640 (0.4)	590 (0.4)	<.0001	0.95	—
Metabolic	6812 (1.6)	2253 (1.7)	2378 (1.5)	2181 (1.5)	.0344	0.99	—
Neurologic	140 767 (32.2)	50 710 (38.4)	49 431 (30.3)	40 626 (28.4)	<.0001	0.94	—
Orthopedic	20 535 (4.7)	5486 (4.2)	6168 (3.8)	8881 (6.2)	<.0001	1.05	—
Other	32 474 (7.4)	5084 (3.9)	14 473 (8.9)	12 917 (9)	<.0001	1.1	—
Prematurity	389 (0.1)	213 (0.2)	103 (0.1)	73 (0.1)	<.0001	0.83	—
Renal	21 578 (4.9)	6919 (5.2)	7883 (4.8)	6776 (4.7)	<.0001	0.99	—
Lower respiratory	4648 (1.1)	2154 (1.6)	1533 (0.9)	961 (0.7)	<.0001	0.89	—
Upper respiratory	1358 (0.3)	708 (0.5)	351 (0.2)	299 (0.2)	<.0001	0.86	—
Rheumatology	3001 (0.7)	648 (0.5)	1146 (0.7)	1207 (0.8)	<.0001	1.06	—
S/P transplant	1739 (0.4)	634 (0.5)	600 (0.4)	505 (0.4)	<.0001	0.97	—
S/P trauma	4081 (0.9)	1681 (1.3)	1442 (0.9)	958 (0.7)	<.0001	0.92	—
Surgical	4176 (1)	1626 (1.2)	1327 (0.8)	1223 (0.9)	<.0001	0.95	—
Procedure completion rate ^b (n = 381 666), n (%)	994 (0.3)	214 (0.3)	424 (0.3)	356 (0.3)	.207	0.99	—

ASA, American Society of Anesthesiology; NPO, nil per os; S/P, status post; —, not applicable.

^a Slope per 1-year increase for weight was 0.5-kg increase.^b Variable was not included until September 2008.

earliest epoch and the most recent epoch.

Sensitivity Analysis

The sensitivity analysis included 256 099 cases from 14 centers that had contributed data during the entire study period. These cases accounted for 58% of the original cohort of 437 842. Results from the sensitivity analysis demonstrated similar trends and effect sizes for most outcomes of interest. Over time,

these centers showed decreases in the use of ketamine (4.4% to 2.7%) and dexmedetomidine (6.5% to 4%) compared with increased use in the overall cohort (data not shown). The overall SAE rate when airway obstruction was included was slightly higher (2.1% vs 1.8%); however, after exclusion of airway obstruction, rates were similar (0.32% vs 0.31%). Risk factors for an SAE were also similar with the exception of risk associated with dental procedures, which

demonstrated significantly higher odds of an SAE (OR = 4.15; 95% CI, 3.41–5.04).

DISCUSSION

Using this multicenter prospective observational cohort study, we provide data on the trends in outpatient procedural sedation in the last decade. Understanding trends in outpatient sedation may help institutions better allocate resources




FIGURE 1

Distribution of sedation providers by epochs. Data were divided into 3 4-year epochs. There was an increase in sedation provided by hospitalists and a decreasing trend in the percentage of sedations provided by other sedation providers (who were not from pediatric critical care, pediatric emergency medicine, or pediatric anesthesiology). EM, emergency medicine.

for sedation programs provided by pediatric subspecialists outside the operating room.

Although most patients sedated in our consortium continue to be in the age group of 1 to 13 years, we noted a decrease in sedation provided for infants in the 1- to 3-month age group, which may reflect an increasing effort to complete some

procedures in this population, especially radiologic procedures, without using sedation.¹⁸ It is possible that awareness of the Food and Drug Administration's warning about potential neurotoxicity from sedation and/or anesthesia may have resulted in elective procedures being delayed until patients are older.^{19,20} It is also possible that some institutions routinely refer patients <3 months of

age to anesthesiologists, who provide general anesthesia in these cases and are thus not included in this database.²¹

Pediatric intensivists and pediatric emergency medicine physicians remained the major providers of procedural sedation throughout the study period. This is likely because sedation and airway management are part of the core competencies of these specialties. Interestingly, our data reveal a significant, increasing trend in sedation provided by pediatric hospitalists throughout the study period as this subspecialty has grown. Training and supporting pediatric hospitalists to provide procedural sedation has the potential to avoid unnecessary referrals to anesthesia professionals and to decrease painful procedures done without sedation, as reported by Srinivasan et al.^{6,22,23} The increasing trend in sedation provided by the hospitalists in this study should concern pediatric hospital medicine program directors because Librizzi et al²⁴ reported that the majority of the hospitalists (fellowship as well as nonfellowship trained) surveyed perceived they had not achieved competency in sedation. Given that the American Board of Medical Specialties has recognized pediatric hospital medicine as a subspecialty of pediatrics, it is imperative that pediatric hospital medicine program directors inculcate robust sedation training in their curricula.²⁵

We also found a significantly decreasing trend in the other providers providing sedation. This category includes radiologists, nurse anesthetists, other advanced practice nurses or physician's assistants, physician trainees, nurses, surgeons, and general pediatricians. This decrease is likely explained by the fact that many pediatric hospitals are moving toward a sedation team-based model to provide sedation services and are becoming less dependent on the single-operator




FIGURE 2

Percentage of sedations with drug category by year. Although propofol was the most commonly used sedative, there were notable decreases in the use of chloral hydrate and pentobarbital over the study period.

TABLE 2 SAE Rates by Epoch

SAE	Overall (N = 437 842), n (%)	95% CI	2007–2010 (N = 131 959), n (%)	2011–2014 (N = 162 954), n (%)	2014–2018 (N = 142 929), n (%)	P for Trend
Overall	7.802 (1.78)	1.74–1.82	1777 (1.35)	3529 (2.17)	2496 (1.75)	<.001
Overall without airway obstruction	1343 (0.31)	0.29–0.32	303 (0.23)	515 (0.32)	525 (0.37)	<.001
SAE type						
Airway obstruction	6805 (1.55)	1.52–1.59	1529 (1.16)	3186 (1.96)	2090 (1.46)	<.001
Laryngospasm	1112 (0.25)	0.24–0.27	228 (0.17)	441 (0.27)	443 (0.31)	<.001
Unplanned admission and/or increased level of care	210 (0.05)	<0.01–0.05	78 (0.06)	56 (0.03)	76 (0.05)	.527
Emergency anesthesia consult	52 (0.01)	0–0.02	4 (0)	24 (0.01)	24 (0.02)	.001
Aspiration	47 (0.01)	0–0.02	8 (0.01)	20 (0.01)	19 (0.01)	.070
Cardiac arrest	13 (<0.01)	0–<0.01	3 (<0.01)	4 (<0.01)	6 (<0.01)	.349
Death	0 (0)	—	0 (0)	0 (0)	0 (0)	—

—, not applicable.


model. The American Academy of Pediatrics has expressed concerns about increased adverse events associated with the single-operator model for providing procedural sedation.²⁶ Our data support the concept that pediatric sedation is becoming a specialty aspect of pediatric practice and should be considered as such for training and credentialing. The 2019 American Academy of Pediatrics guidelines for procedural sedation recommend the

involvement of an independent observer (independent of performing or assisting with the procedure) who is trained in airway rescue and whose only responsibility is to monitor the patient undergoing deep procedural sedation.²⁷ Additionally, the American Society of Anesthesiologists and the US Food and Drug Administration specify that propofol used for sedation and anesthesia should be administered by sedation and anesthesia providers who are trained

in their administration and are not involved in the conduct of the surgical or diagnostic procedure.²⁸

Consistent with previous publications, our study found that sedation providers often provide sedation for pediatric patients requiring radiologic, hematologic-oncologic, and gastrointestinal procedures.^{4,5,14} With the shift from use of computed tomography to magnetic resonance imaging in infants and children due to concerns about ionizing radiation, there is an increasing need for sedation because of the longer duration of magnetic resonance imaging as well as the increased need for patient immobility and cooperativeness.^{29–32}

Propofol, because of its quick onset and emergence properties, remains the most favored agent in procedural sedation, especially for radiologic imaging. It is used in combination with fentanyl or ketamine for painful procedures.^{12,33} We observed a decreasing trend in the use of chloral hydrate and pentobarbital. A decrease in chloral hydrate use is almost certainly due to nonavailability of the oral formulation of chloral hydrate in the United States after the discontinuation of its manufacture. A minority of institutions compound chloral hydrate using the raw ingredients.³⁴ The trend toward less use is appropriate because chloral hydrate has a narrow therapeutic index and

**FIGURE 3**

Results from the multivariable logistic regression model of SAEs. Risk factors were examined for their association with an SAE. Results are presented as model-adjusted ORs (green diamonds) with bars spanning the 95% CIs. The dashed line crossing 1 shows the line of no association. ASA, American Society of Anesthesiologists; NPO, nil per os.

no antidote for toxicity. Its use has been associated with prolonged sedation or clinical resedation and has been linked to multiple deaths during procedural sedation.³⁵ Unlike chloral hydrate, pentobarbital is most often delivered intravenously and has a rapid onset of action; however, the duration of sedation can be prolonged, making it a less viable option for high-volume outpatient radiologic services, which rely on a quick patient turnover.³⁶ Miller et al³⁷ have also reported a similar trend in sedative use (decreasing use of chloral hydrate and pentobarbital) across children's hospital emergency departments.

Contrary to the situation with chloral hydrate and pentobarbital, there was an increasing trend in the use of dexmedetomidine, especially via the intranasal route. Dexmedetomidine, a central α_2 agonist, has anxiolytic and mild analgesic properties while preserving airway tone and respiratory drive in patients. Compared with chloral hydrate, dexmedetomidine does not induce neuroapoptosis and may in fact be neuroprotective, especially when used with sedatives like propofol and especially in infants and young children.³⁸ Additionally, dexmedetomidine has a quicker onset of sedation, faster recovery, and higher success rate compared with chloral hydrate, especially when used for short radiologic procedures or auditory brainstem-response testing.^{39–41} Previous studies from the PSRC have reported high success rates with intravenous and intranasal administration of dexmedetomidine as well as a low association with adverse events.^{42,43} Sedation providers should consider the use of dexmedetomidine, especially in infants and young children, for short, nonpainful procedures given its distinct advantages over chloral hydrate.

Our data indicate a small increase in the SAE rate in the most recent epoch

compared with previous ones, but overall, the adverse event rate is low and consistent with what has been previously reported from the PSRC.^{14,15} Furthermore, we found, consistently through all epochs, that conditions such as prematurity, upper respiratory tract infection, asthma, developmental delay, and obstructive sleep apnea, as well as procedures such as gastrointestinal or dental procedures, can have a higher propensity for an adverse event, especially airway events. Similar to what Coté et al³⁵ found in their report, we found that the combination of medications is also associated with a higher incidence of adverse airway events through all epochs. We are unable to discern if the adverse events from a combination of medications in our study were related to the drugs themselves, drug dosing errors, drug interactions, or differences in monitoring standards. Although Coté et al³⁵ reported death or neurologic injury in 72% of their patients (36 of 50) who received a combination of 2 or more drugs (mostly long-acting drugs with long half-lives, such as chloral hydrate and pentobarbital), our study had no deaths or severe neurologic injury. The lack of mortality in our study despite drug combinations is probably because shorter-acting agents, such as propofol, were used in combination with opioids or benzodiazepines (both with reversal agents, namely naloxone and flumazenil). Furthermore, when propofol is combined with ketamine, ketamine maintains airway reflexes and is less likely to be associated with respiratory depression.⁴⁴

Authors of previous studies have reported limitations of the PSRC database.^{4,9,15} The PSRC institutions enter data voluntarily and are therefore highly motivated and organized sedation systems that would outperform other less-controlled systems that are not

a part of the PSRC. Another limitation is that the PSRC database does not capture continuous intraprocedure hemodynamic monitoring data but reports a change of 30% or more from baseline. Although most centers use the American Academy of Pediatrics–recommended monitoring and discharge criteria, the PSRC does not mandate these monitoring criteria.^{27,45} The PSRC database also does not capture the depth of sedation nor medication dosing, and it is possible that the depth of sedation could have a bearing on adverse events reported. Determination of the depth of sedation requires patient stimulation and is contrary to the goal of procedure completion with adequate anxiolysis, hypnosis, analgesia, and immobility if required.⁴⁶

CONCLUSIONS

In this article, we report the latest trends in outpatient pediatric procedural sedation in the PSRC database. We report an increase in pediatric hospitalists providing sedation and a significant decrease in the use of chloral hydrate and pentobarbital by providers.

ACKNOWLEDGMENTS

We thank the Emory University and Children's Healthcare of Atlanta Biostatistics Core for their help with statistical analysis and Kathleen Loudon, ELS, who provided editorial assistance. We also thank all the participating members of the PSRC.

ABBREVIATIONS

CI: confidence interval
OR: odds ratio
PSRC: Pediatric Sedation Research Consortium
SAE: serious adverse event

Address correspondence to Pradip P. Kamat, MD, MBA, FCCM, School of Medicine, Emory University, 4th Floor PICU, Children's Healthcare of Atlanta @Egleston, 1405 Clifton Rd NE, Atlanta, GA 30322. E-mail: pradip.kamat@choa.org

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2020 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: No external funding.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

COMPANION PAPER: A companion to this article can be found online at www.pediatrics.org/cgi/doi/10.1542/peds.2020-0446.

REFERENCES

1. Couloures KG, Beach M, Cravero JP, Monroe KK, Hertzog JH. Impact of provider specialty on pediatric procedural sedation complication rates. *Pediatrics*. 2011;127(5). Available at: www.pediatrics.org/cgi/content/full/127/5/e1154
2. Mason KP. Sedation trends in the 21st century: the transition to dexmedetomidine for radiological imaging studies. *Paediatr Anaesth*. 2010;20(3):265–272
3. Havidich JE, Cravero JP. The current status of procedural sedation for pediatric patients in out-of-operating room locations. *Curr Opin Anaesthesiol*. 2012;25(4):453–460
4. Kamat PP, McCracken CE, Gillespie SE, et al. Pediatric critical care physician-administered procedural sedation using propofol: a report from the Pediatric Sedation Research Consortium Database. *Pediatr Crit Care Med*. 2015; 16(1):11–20
5. Mallory MD, Baxter AL, Yanosky DJ, Cravero JP; Pediatric Sedation Research Consortium. Emergency physician-administered propofol sedation: a report on 25,433 sedations from the Pediatric Sedation Research Consortium. *Ann Emerg Med*. 2011; 57(5):462–468.e1
6. Srinivasan M, Turmelle M, Depalma LM, Mao J, Carlson DW. Procedural sedation for diagnostic imaging in children by pediatric hospitalists using propofol: analysis of the nature, frequency, and predictors of adverse events and interventions. *J Pediatr*. 2012;160(5): 801–806.e1
7. Cravero JP, Coté CJ. Raising the bar for pediatric sedation studies and trials. *Paediatr Anaesth*. 2015;25(1):2–4
8. Kamat PP, Hollman GA, Simon HK, Fortenberry JD, McCracken CE, Stockwell JA. Current state of institutional privileging profiles for pediatric procedural sedation providers. *Hosp Pediatr*. 2015;5(9): 487–494
9. Mallory MD, Travers C, McCracken CE, Hertzog J, Cravero JP. Upper respiratory infections and airway adverse events in pediatric procedural sedation. *Pediatrics*. 2017;140(1): e20170009
10. Havidich JE, Beach M, Dierdorf SF, Onega T, Suresh G, Cravero JP. Preterm versus term children: analysis of sedation/anesthesia adverse events and longitudinal risk. *Pediatrics*. 2016; 137(3):e20150463
11. Grunwell JR, Travers C, McCracken CE, et al. Procedural sedation outside of the operating room using ketamine in 22,645 children: a report from the Pediatric Sedation Research Consortium. *Pediatr Crit Care Med*. 2016;17(12):1109–1116
12. Grunwell JR, Travers C, Stormorken AG, et al. Pediatric procedural sedation using the combination of ketamine and propofol outside of the emergency department: a report from the Pediatric Sedation Research Consortium. *Pediatr Crit Care Med*. 2017;18(8):e356–e363
13. Scherrer PD, Mallory MD, Cravero JP, Lowrie L, Hertzog JH, Berkenbosch JW; Pediatric Sedation Research Consortium. The impact of obesity on pediatric procedural sedation-related outcomes: results from the Pediatric Sedation Research Consortium. *Paediatr Anaesth*. 2015;25(7):689–697
14. Cravero JP, Beach ML, Blike GT, Gallagher SM, Hertzog JH; Pediatric Sedation Research Consortium. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium. *Anesth Analg*. 2009;108(3): 795–804
15. Cravero JP, Blike GT, Beach M, et al; Pediatric Sedation Research Consortium. Incidence and nature of adverse events during pediatric sedation/anesthesia for procedures outside the operating room: report from the Pediatric Sedation Research Consortium. *Pediatrics*. 2006;118(3): 1087–1096
16. Beach ML, Cohen DM, Gallagher SM, Cravero JP. Major adverse events and relationship to nil per os status in pediatric sedation/anesthesia outside the operating room: a report of the Pediatric Sedation Research Consortium. *Anesthesiology*. 2016; 124(1):80–88
17. Hertzog JH, Preisberga K, Penfil S. The incidence and nature of allergic and anaphylactic reactions during pediatric procedural sedation: a report from the Pediatric Sedation Research Consortium. *Hosp Pediatr*. 2019;9(1): 16–23
18. Parad RB. Non-sedation of the neonate for radiologic procedures. *Pediatr Radiol*. 2018;48(4):524–530
19. FDA Drug Safety Communication. FDA review results in new warnings about

- using general anesthetics and sedation drugs in young children and pregnant women. 2016. Available at: <https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm>. Accessed September 28, 2019
20. FDA Drug Safety Communication. FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. 2017. Available at: <https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm>. Accessed September 28, 2019
 21. Daud YN, Carlson DW. Pediatric sedation. *Pediatr Clin North Am*. 2014; 61(4):703–717
 22. Srinivasan M, Bhaskar S, Carlson DW. Variation in procedural sedation practices among children's hospitals. *Hosp Pediatr*. 2015;5(3):148–153
 23. Turmelle M, Moscoso LM, Hamlin KP, Daud YN, Carlson DW. Development of a pediatric hospitalist sedation service: training and implementation. *J Hosp Med*. 2012;7(4):335–339
 24. Librizzi J, Winer JC, Banach L, Davis A. Perceived core competency achievements of fellowship and non-fellowship-trained early career pediatric hospitalists. *J Hosp Med*. 2015;10(6):373–379
 25. Jerardi KE, Fisher E, Rassbach C, et al; Council of Pediatric Hospital Medicine Fellowship Directors. Development of a curricular framework for pediatric hospital medicine fellowships. *Pediatrics*. 2017;140(1):e20170698
 26. Agarwal R, Kaplan A, Brown R, Coté CJ. Concerns regarding the single operator model of sedation in young children. *Pediatrics*. 2018;141(4):e20172344
 27. Coté CJ, Wilson S; American Academy of Pediatrics; American Academy of Pediatric Dentistry. Guidelines for monitoring and management of pediatric patients before, during, and after sedation for diagnostic and therapeutic procedures. *Pediatrics*. 2019;143(6):e20191000
 28. US Food and Drug Administration. Drugs/diprivan. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019627s066lbl.pdf. Accessed September 28, 2019
 29. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. *N Engl J Med*. 2007; 357(22):2277–2284
 30. Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. *BMJ*. 2013;346:f2360
 31. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. *Lancet*. 2012;380(9840):499–505
 32. Masaracchia MM, Tsapakos MJ, McNulty NJ, Beach ML. Changing the paradigm for diagnostic MRI in pediatrics: don't hold your breath. *Paediatr Anaesth*. 2017;27(9):880–884
 33. Chidambaram V, Costandi A, D'Mello A. Propofol: a review of its role in pediatric anesthesia and sedation. *CNS Drugs*. 2015;29(7):543–563
 34. Mason KP. Challenges in paediatric procedural sedation: political, economic, and clinical aspects. *Br J Anaesth*. 2014;113(suppl 2):ii48–ii62
 35. Coté CJ, Karl HW, Notterman DA, Weinberg JA, McCloskey C. Adverse sedation events in pediatrics: analysis of medications used for sedation. *Pediatrics*. 2000;106(4):633–644
 36. Moro-Sutherland DM, Algren JT, Louis PT, Kozinetz CA, Shook JE. Comparison of intravenous midazolam with pentobarbital for sedation for head computed tomography imaging. *Acad Emerg Med*. 2000;7(12):1370–1375
 37. Miller AF, Monuteaux MC, Bourgeois FT, Fleegler EW. Variation in pediatric procedural sedations across children's hospital emergency departments. *Hosp Pediatr*. 2018;8(1):36–43
 38. Perez-Zoghbi JF, Zhu W, Grafe MR, Brambrink AM. Dexmedetomidine-mediated neuroprotection against sevoflurane-induced neurotoxicity extends to several brain regions in neonatal rats. *Br J Anaesth*. 2017; 119(3):506–516
 39. Cozzi G, Norbedo S, Barbi E. Intranasal dexmedetomidine for procedural sedation in children, a suitable Alternative to chloral hydrate. *Paediatr Drugs*. 2017;19(2):107–111
 40. Reynolds J, Sedillo DJ. The evolving role of intranasal dexmedetomidine for pediatric procedural sedation. *Hosp Pediatr*. 2018;8(2):115–117
 41. Reynolds J, Rogers A, Medellin E, Guzman JA, Watcha MF. A prospective, randomized, double-blind trial of intranasal dexmedetomidine and oral chloral hydrate for sedated auditory brainstem response (ABR) testing. *Paediatr Anaesth*. 2016;26(3):286–293
 42. Sulton C, Kamat P, Mallory M, Reynolds J. The use of intranasal dexmedetomidine and midazolam for sedated magnetic resonance imaging in children: a report from the Pediatric Sedation Research Consortium. *Pediatr Emerg Care*. 2020;36(3):138–142
 43. Sulton C, McCracken C, Simon HK, et al. Pediatric procedural sedation using dexmedetomidine: a report from the Pediatric Sedation Research Consortium. *Hosp Pediatr*. 2016;6(9): 536–544
 44. Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. *Ann Emerg Med*. 2011;57(5):449–461
 45. Coté CJ, Wilson S; American Academy of Pediatrics; American Academy of Pediatric Dentistry. Guidelines for monitoring and management of pediatric patients before, during, and after sedation for diagnostic and therapeutic procedures: update 2016. *Pediatrics*. 2016;138(1):e20161212
 46. Coté CJ, Cravero J. Brave new world: do we need it, do we want it, can we afford it? *Paediatr Anaesth*. 2011;21(9): 919–923